¥xÅç¥X2´Ú¤é¥»¶i¤f¤h¦h°à±ù¹AÃĤΫª÷ÄݶW¼Ð
¡i©ú³ø±M°T¡j¥xÆWªº¹«~ÃĪ«ºÞ²z¸p©P¤G(5¤é)¤W¤È¤½¥¬Ãä¹Ò¬dÅ礣¦X®æ¦W³æ¡A¦@¦³14´Ú¶i¤f²£«~¥¼¯à³q¹L©â¬d¡A¨ä¤¤¥]¬A¨â§å¤À§O¨Ó¦Û¤é¥»ºµ¥»¡B¦õ¶PªºÂA¤h¦h°à±ù¡A¾DÅç¥X¸T¥Î¹AÃĤΫª÷ÄÝÂð¶W¼Ð¡A¥²¶·°h¹B©Î¾P·´¡C
¾Ú¹Ãĸp¤½¥¬¡A¤£¦X®æ¦W³æ¥]¬A·N¤j§QªºµÔµæ¡B¼w°êªº»¯ó¬õ¯ù¡B¤ñ§Q®ÉªºµâU¡B¤j³°¥X¤fªº¬e§ûµ¥¡A¤Wz§¡¦]´Ý¯d¹AÃĤ£²Å¥x·í§½³W©w¡C¦¹¥~¡A·í§½¤À§O¦b¦õ¶P²£¤h¦h°à±ù¤¤¡AÀË¥X´Ý¯d0.21ppm¹AÃÄ¡u¬tÔrÂΞqÓi((Flonicamid)¡v©M0.33ppm¡uÙæÂΞqÓi(cyantraniliprole)¡v¡F¨Ã¦bºµ¥»²£¤h¦h°à±ù¤¤ÀË¥X0.52ppm¬tÔrÂΞqÓi¡A¥H¤Î¨C¤½¤ç0.09²@§Jªº«ª÷ÄÝÂð¡C
¹Ãĸp¥_°ÏºÞ²z¤¤¤ß¬ìªø³¯¼y¸Î«ü¥X¡A¤Wz¨â´Ú¹AÃĬҤ£±o¨Ï¥Î©ó¤h¦h°à±ù¡A³o¥ç¬O¹L¥h¥b¦~¥H¨Ó²Ä2¦¸µo²{¦³¤é¥»¤h¦h°à±ù¹H³W¡C·í§½±N¥[±j©âÅç¯A¨Æ²£«~¤Î¶i¤f°Ó¡A©â¬d¶q¥Ñ20%´£¤É¨ì50%¡FY¦Aµo²{¹H³W¡A«K·|¸¨¹êÀˬd¥þ³¡¬ÛÃö²£«~¡C